The missing piece of the puzzle holding up a key Alzheimer’s drug.
- Posted on Oct 20, 2026
After decades of research, American scientists may finally be closing in on new ways to fight Alzheimer’s disease.... Read More
Beyond Amyloid: Why Protecting Synapses Could Change Alzheimer’s Prevention with Dr. Frank Longo
- Posted on Oct 8, 2026
Meryl Comer talks with Dr. Frank Longo, of PharmatrophiX. Dr. Longo’s work shifts the question from how to clear amyloid that has built up in the brain to how to prevent pathological tau from building up and at the same time keeping the brain's communication network strong enough to withstand damage in the first place... Read More
CurePSP Announces Enrollment of First Participant in the PSP Trial Platform
- Posted on Aug 7, 2026
Progressive supranuclear palsy (PSP) is a rare brain disorder that can mimic Parkinson’s disease in loss of balance, movement disorders and stiffness. There is no cure and no approved treatment, in part due to the limited number of clinical trials for potential treatments. ... Read More
Dr. Frank Longo, Stanford University professor of neurology and PharmatrophiX co-founder, joins ‘Squawk Box’ to discuss the company’s new Alzheimer’s drug LM11A-31
- Posted on Jul 28, 2026
How the new drug approaches treatment differently from existing Alzheimer’s therapies, and more.... Read More
PharmatrophiX Selected for Landmark UCSF-led platform trial in rare neurodegenerative disease; Unveils New Data at Tau Global Conference
- Posted on May 14, 2026
PharmatrophiX unveiled preclinical data at the Global Tau Conference further supporting evidence that LM11A-31 is a multi-action shield for the brain's connections... Read More
p75 neurotrophin receptor modulation in mild to moderate Alzheimer’s disease
- Posted on May 17, 2024
The 26-week Phase 2a trial met its primary endpoint for safety and tolerability, with biomarker and imaging signals supporting further study.... Read More
The Alzheimer’s drug working upstream of amyloid.
- Posted on Aug 19, 2026
New imaging analysis from the Phase 2a trial of a new small molecule drug shows dose-dependent preservation of whole-brain connectivity. ... Read More
Targeting Upstream Neurodegeneration: LM11A-31 in Alzheimer’s Disease and PSP
- Posted on May 7, 2026
David Setboun, Pharm.D., MBA, CEO of PharmatrophiX, and Frank M. Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism targeting p75 signaling and its potential to modify neurodegenerative disease biology.... Read More
A better Alzheimer’s drug?
- Posted on Feb 25, 2026
Stanford Medicine profiles LM11A-31 as a synapse-protective approach to slowing neurodegeneration.... Read More
p75 receptor modulation slows biomarkers and preserves visuospatial function
- Posted on Dec 2, 2025
CTAD coverage reports p-tau217 and synaptic-proteome signals over 26 weeks.... Read More
New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients
- Posted on Apr 3, 2025
NIA summarizes safety and biomarker findings supporting larger LM11A-31 trials.... Read More
Alzheimer’s from a New Angle
- Posted on Feb 11, 2016
Dr. Frank Longo on hope, innovation, and a radical departure from traditional Alzheimer’s research... Read More